0001104659-19-070217.txt : 20191205 0001104659-19-070217.hdr.sgml : 20191205 20191205163036 ACCESSION NUMBER: 0001104659-19-070217 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191204 FILED AS OF DATE: 20191205 DATE AS OF CHANGE: 20191205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ende Eric J CENTRAL INDEX KEY: 0001494386 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 191270689 MAIL ADDRESS: STREET 1: C/O MATINAS BIOPHARMA HOLDINGS, INC. STREET 2: 1545 ROUTE 206 SOUTH, SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 tm1924557-1_4.xml OWNERSHIP DOCUMENT X0306 4 2019-12-04 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001494386 Ende Eric J C/O AVADEL PHARMACEUTICALS PLC BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK DUBLIN L2 15 IRELAND 1 0 0 0 ADSs 2019-12-04 4 P 0 10000 5.97 A 47900 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.94 to $5.99, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. /s/ Phillandas T. Thompson as attorney in fact for Eric J. Ende 2019-12-05